-
- Joerg Timm
- 1Partners AIDS Research Center and Infectious Disease Division, Howard Hughes Medical Institute
-
- Georg M. Lauer
- 1Partners AIDS Research Center and Infectious Disease Division, Howard Hughes Medical Institute
-
- Daniel G. Kavanagh
- 1Partners AIDS Research Center and Infectious Disease Division, Howard Hughes Medical Institute
-
- Isabelle Sheridan
- 3Nuffield Department of Clinical Medicine, Peter Medawar Building, University of Oxford, Oxford OX1 3SY, England, UK
-
- Arthur Y. Kim
- 1Partners AIDS Research Center and Infectious Disease Division, Howard Hughes Medical Institute
-
- Michaela Lucas
- 3Nuffield Department of Clinical Medicine, Peter Medawar Building, University of Oxford, Oxford OX1 3SY, England, UK
-
- Thillagavathie Pillay
- 3Nuffield Department of Clinical Medicine, Peter Medawar Building, University of Oxford, Oxford OX1 3SY, England, UK
-
- Kei Ouchi
- 1Partners AIDS Research Center and Infectious Disease Division, Howard Hughes Medical Institute
-
- Laura L. Reyor
- 1Partners AIDS Research Center and Infectious Disease Division, Howard Hughes Medical Institute
-
- Julian Schulze zur Wiesch
- 1Partners AIDS Research Center and Infectious Disease Division, Howard Hughes Medical Institute
-
- Rajesh T. Gandhi
- 1Partners AIDS Research Center and Infectious Disease Division, Howard Hughes Medical Institute
-
- Raymond T. Chung
- 2Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
-
- Nina Bhardwaj
- 4New York University School of Medicine, New York, NY 10016
-
- Paul Klenerman
- 3Nuffield Department of Clinical Medicine, Peter Medawar Building, University of Oxford, Oxford OX1 3SY, England, UK
-
- Bruce D. Walker
- 1Partners AIDS Research Center and Infectious Disease Division, Howard Hughes Medical Institute
-
- Todd M. Allen
- 1Partners AIDS Research Center and Infectious Disease Division, Howard Hughes Medical Institute
抄録
<jats:p>In the setting of acute hepatitis C virus (HCV) infection, robust HCV-specific CD8+ cytotoxic T lymphocyte (CTL) responses are associated with initial control of viremia. Despite these responses, 70–80% of individuals develop persistent infection. Although viral escape from CD8 responses has been illustrated in the chimpanzee model of HCV infection, the effect of CD8 selection pressure on viral evolution and containment in acute HCV infection in humans remains unclear. Here, we examined viral evolution in an immunodominant human histocompatibility leukocyte antigen (HLA)-B8–restricted NS3 epitope in subjects with acute HCV infection. Development of mutations within the epitope coincided with loss of strong ex vivo tetramer and interferon γ enzyme-linked immunospot responses, and endogenous expression of variant NS3 sequences suggested that the selected mutations altered processing and presentation of the variant epitope. Analysis of NS3 sequences from 30 additional chronic HCV-infected subjects revealed a strong association between sequence variation within this region and expression of HLA-B8, supporting reproducible allele-specific selection pressures at the population level. Interestingly, transmission of an HLA-B8–associated escape mutation to an HLA-B8 negative subject resulted in rapid reversion of the mutation. Together, these data indicate that viral escape from CD8+ T cell responses occurs during human HCV infection and that acute immune selection pressure is of sufficient magnitude to influence HCV evolution.</jats:p>
収録刊行物
-
- The Journal of Experimental Medicine
-
The Journal of Experimental Medicine 200 (12), 1593-1604, 2004-12-20
Rockefeller University Press
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1361699995251121536
-
- NII論文ID
- 30017434499
-
- ISSN
- 15409538
- 00221007
- http://id.crossref.org/issn/00221007
-
- データソース種別
-
- Crossref
- CiNii Articles